Chiu HY, et al. - Between 2011 and 2018, about 500 subjects were assessed to examine the predictors of relapse after withdrawal of ustekinumab in psoriasis cases. Authors obtained 49.3%, 12.6%, 5.3%, 4.7%, and 1.6% of cumulative probabilities of relapse-free at 6 months, 12 months, 18 months, 24 months and 36 months of withdrawal from ustekinumab treatment, respectively. They noticed an improvement in maximum Psoriasis Area and Severity Index (PASI). They recorded family history of psoriasis, chronic kidney disease, and immunosuppressants use while off ustekinumab as significant predictors of time to relapse following ustekinumab discontinuation. Hence, withdrawal of ustekinumab from cases with well-controlled psoriasis could not be advised due to high rates of relapse.